Unusual 11 Mid-Day Movers 7/22: MEG, SOMX, ONXX, OREX Higher; HEB, ATI, AMD, SUPX Lower
Up)
Media General, Inc. (NYSE: MEG) 108.4% HIGHER; reports Q2 EPS from continuing operations of $0.57, versus the analyst estimate of ($0.24). Revenue for the quarter was $163.83 million, versus the consensus of $168.13 million.
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) 29.4% HIGHER; spiking today amid no company-specific news. SeekingAlpha.com did a short write-up on the stock earlier, which could be driving upside.
Hemispherx BioPharma (AMEX: HEB) 28% LOWER; sinking today amid the company's conference call to discuss recent Influenze research initiatives. Hemispherx said it is targeting 25-50 million doses of Ampligen per year, as well as at least 100 million doses of Alferon LDO at capacity, two initiatives which are expected to cost the company about $10 million.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) 25.3% HIGHER; Bayer HealthCare Pharmaceuticals and Onyx Pharma today announced that their first cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Click here to see the full report.
Orexigen Therapeutics, Inc. (Nasdaq: OREX) 20% HIGHER; seeing follow-through momentum from Monday, when the company reported all three of its remaining trials on Contrave met their primary endpoints. Shares of Orexigen have already jumped 56% this week.
Oriental Financial Group (NYSE: OFG) 17.6% HIGHER; reports Q2 EPS of $2.04, versus the analyst estimate of $0.64.
Allegheny Technologies Incorporated (NYSE: ATI) 17.5% LOWER; reports Q2 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter was $710 million, versus the consensus of $816.58 million.
Gentex (Nasdaq: GNTX) 17.3% HIGHER; reports Q2 EPS of $0.09, 4 cents better than the analyst estimate of $0.05. Revenue for the quarter was $117.3 million, versus the consensus of $115 million.
Advanced Micro Devices (NYSE: AMD) 13% LOWER; reports Q2 loss of $0.49, (including a $0.13 favorable impact), or a loss of $0.62, versus the analyst estimate of ($0.47). Revenue for the quarter was $1.184 billion, versus the consensus of $1.13 billion.
Supertex (Nasdaq: SUPX) 12.9% LOWER; reports Q1 EPS of $0.13, 4 cents better than the analyst estimate of $0.09. Revenue for the quarter was $13.6 million, versus the consensus of $15.91 million.
Pharmaceutical Product Development (Nasdaq: PPDI) 12.8% LOWER; reports Q2 EPS from continuing operations of $0.33, 4 cents better than the analyst estimate of $0.29. Revenue for the quarter was $355.2 million, versus the consensus of $334.38 million.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) 29.4% HIGHER; spiking today amid no company-specific news. SeekingAlpha.com did a short write-up on the stock earlier, which could be driving upside.
Hemispherx BioPharma (AMEX: HEB) 28% LOWER; sinking today amid the company's conference call to discuss recent Influenze research initiatives. Hemispherx said it is targeting 25-50 million doses of Ampligen per year, as well as at least 100 million doses of Alferon LDO at capacity, two initiatives which are expected to cost the company about $10 million.
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) 25.3% HIGHER; Bayer HealthCare Pharmaceuticals and Onyx Pharma today announced that their first cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Click here to see the full report.
Orexigen Therapeutics, Inc. (Nasdaq: OREX) 20% HIGHER; seeing follow-through momentum from Monday, when the company reported all three of its remaining trials on Contrave met their primary endpoints. Shares of Orexigen have already jumped 56% this week.
Oriental Financial Group (NYSE: OFG) 17.6% HIGHER; reports Q2 EPS of $2.04, versus the analyst estimate of $0.64.
Allegheny Technologies Incorporated (NYSE: ATI) 17.5% LOWER; reports Q2 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter was $710 million, versus the consensus of $816.58 million.
Gentex (Nasdaq: GNTX) 17.3% HIGHER; reports Q2 EPS of $0.09, 4 cents better than the analyst estimate of $0.05. Revenue for the quarter was $117.3 million, versus the consensus of $115 million.
Advanced Micro Devices (NYSE: AMD) 13% LOWER; reports Q2 loss of $0.49, (including a $0.13 favorable impact), or a loss of $0.62, versus the analyst estimate of ($0.47). Revenue for the quarter was $1.184 billion, versus the consensus of $1.13 billion.
Supertex (Nasdaq: SUPX) 12.9% LOWER; reports Q1 EPS of $0.13, 4 cents better than the analyst estimate of $0.09. Revenue for the quarter was $13.6 million, versus the consensus of $15.91 million.
Pharmaceutical Product Development (Nasdaq: PPDI) 12.8% LOWER; reports Q2 EPS from continuing operations of $0.33, 4 cents better than the analyst estimate of $0.29. Revenue for the quarter was $355.2 million, versus the consensus of $334.38 million.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
You May Also Be Interested In
- Notable ETF Movers of the Day 05/25: (EWZ) (GLD) Higher; (VXX) (UNG) Lower
- Trading Radar for 05/25: Mentor Graphics (MENT), Tsakos Energy (TNP) Report
- Notable Mergers and Acquisitions of the Day 05/23: (MON) (STX) (ORCL)
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Unusual 11 Mid-Day MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
